Completed PHASE3 INTERVENTIONAL NCT00021671

Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission

Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Interventions Ampicillin sodium Erythromycin Metronidazole Nevirapine

Updated 6 times since 2017 Last updated: Oct 28, 2021 Completion: Nov 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00021671, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
National Institute on Drug Abuse (NIDA)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Research Triangle Park, United States